The clean safety data is incrementally positive but Phase 1 efficacy readouts are needed for material valuation impact. Monitor for updates on dose escalation and preliminary efficacy endpoints.
Price Chart
Executive Summary
Kairos Pharma announced interim safety data from its Phase 1 trial of ENV-105 + osimertinib in EGFR-mutated NSCLC, reporting zero Grade 3+ adverse events in 13 patients. The clean safety profile supports continued development but does not provide efficacy data or financial impact. No financial figures were disclosed.
Key Facts
- Zero Grade 3+ toxicities from ENV-105 in 13 treated patients
- Phase 1 trial evaluating ENV-105 (carotuximab) + osimertinib in EGFR-mutated NSCLC
- Interim safety data reported on July 15, 2026
- Company is a clinical-stage biotech with $7M market cap
Financial Impact
No financial data reported; capital requirement for Phase 1 completion undisclosed
Risk Factors
- Phase 1 safety data is only on 13 patients; larger trials may reveal toxicities
- No efficacy data yet; combination may fail to improve outcomes
- Pre-revenue company relies on future financing for development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-033289 |
| Exhibit: ex99-1.htm | 0001493152-26-033289 |
| Document: 0001493152-26-033289-index-headers.html | 0001493152-26-033289 |
| Document: 0001493152-26-033289-index.html | 0001493152-26-033289 |
| Document: 0001493152-26-033289.txt | 0001493152-26-033289 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $1.15 $0.8287 | ▼ −27.94% | ▼ −27.80% | $0.5590 (−51.39%) |
Jul 22, 2026 13w ago | 8-K | $0.3127 $0.2990 | ▼ −4.38% | ▼ −1.98% | $0.5590 (+78.77%) |
Jul 15, 2026 14w ago | 8-K | $0.3180 $0.3127 | ▼ −1.67% | ▼ −0.69% | $0.5590 (+75.79%) |
Jun 4, 2026 20w ago | 8-K | $0.4660 $0.4580 | ▼ −1.72% | ▲ +0.84% | $0.5590 (+19.96%) |
May 26, 2026 21w ago | DEFA14A | $0.5170 $0.4620 | ▼ −10.64% | ▼ −11.11% | $0.5590 (+8.12%) |
Feb 26, 2026 34w ago | 8-K | $0.5520 $0.6560 | ▲ +18.84% | ▲ +19.97% | $0.5590 (+1.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers